Stryker Co. (NYSE:SYK) Shares Sold by Everett Harris & Co. CA

Everett Harris & Co. CA trimmed its holdings in shares of Stryker Co. (NYSE:SYK) by 2.6% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 6,297 shares of the medical technology company’s stock after selling 168 shares during the period. Everett Harris & Co. CA’s holdings in Stryker were worth $2,267,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors also recently modified their holdings of the stock. State Street Corp increased its stake in Stryker by 2.2% during the 3rd quarter. State Street Corp now owns 14,582,959 shares of the medical technology company’s stock worth $5,279,788,000 after buying an additional 316,404 shares during the period. FMR LLC grew its stake in Stryker by 3.0% during the 3rd quarter. FMR LLC now owns 7,306,994 shares of the medical technology company’s stock valued at $2,639,725,000 after purchasing an additional 215,782 shares in the last quarter. Geode Capital Management LLC increased its holdings in Stryker by 2.5% during the 3rd quarter. Geode Capital Management LLC now owns 6,905,126 shares of the medical technology company’s stock worth $2,484,893,000 after purchasing an additional 165,490 shares during the last quarter. Parnassus Investments LLC purchased a new position in shares of Stryker during the 3rd quarter valued at approximately $762,798,000. Finally, Janus Henderson Group PLC grew its position in shares of Stryker by 1.5% during the third quarter. Janus Henderson Group PLC now owns 1,969,757 shares of the medical technology company’s stock worth $711,594,000 after buying an additional 28,421 shares in the last quarter. Institutional investors and hedge funds own 77.09% of the company’s stock.

Insider Transactions at Stryker

In other Stryker news, CEO Kevin Lobo sold 57,313 shares of the business’s stock in a transaction dated Thursday, November 7th. The stock was sold at an average price of $368.70, for a total value of $21,131,303.10. Following the completion of the sale, the chief executive officer now owns 100,027 shares of the company’s stock, valued at $36,879,954.90. The trade was a 36.43 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 5.90% of the stock is currently owned by insiders.

Stryker Price Performance

Shares of NYSE:SYK opened at $390.90 on Friday. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.22 and a current ratio of 1.91. The company has a market capitalization of $149.02 billion, a PE ratio of 50.37, a price-to-earnings-growth ratio of 2.68 and a beta of 0.95. The stock has a fifty day moving average of $376.56 and a 200-day moving average of $362.38. Stryker Co. has a one year low of $314.93 and a one year high of $406.19.

Stryker (NYSE:SYK) last released its quarterly earnings results on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share for the quarter, beating analysts’ consensus estimates of $3.87 by $0.14. Stryker had a return on equity of 23.86% and a net margin of 13.25%. During the same period last year, the business posted $3.46 earnings per share. As a group, equities analysts anticipate that Stryker Co. will post 13.53 EPS for the current fiscal year.

Stryker Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, January 31st. Shareholders of record on Tuesday, December 31st were paid a dividend of $0.84 per share. This is an increase from Stryker’s previous quarterly dividend of $0.80. This represents a $3.36 annualized dividend and a yield of 0.86%. The ex-dividend date of this dividend was Tuesday, December 31st. Stryker’s payout ratio is 43.30%.

Wall Street Analyst Weigh In

Several brokerages have weighed in on SYK. Piper Sandler reissued an “overweight” rating and set a $420.00 price objective (up from $380.00) on shares of Stryker in a report on Wednesday, October 30th. JPMorgan Chase & Co. upped their price objective on Stryker from $420.00 to $445.00 and gave the company an “overweight” rating in a research note on Wednesday. Stifel Nicolaus lifted their target price on Stryker from $400.00 to $440.00 and gave the stock a “buy” rating in a research report on Wednesday. JMP Securities restated a “market perform” rating on shares of Stryker in a research note on Tuesday, January 7th. Finally, Robert W. Baird boosted their price objective on shares of Stryker from $378.00 to $405.00 and gave the company an “outperform” rating in a research report on Wednesday, October 30th. Five investment analysts have rated the stock with a hold rating and sixteen have given a buy rating to the stock. According to MarketBeat.com, Stryker currently has an average rating of “Moderate Buy” and an average target price of $419.37.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.